Form 4: Bristol-Myers Squibb Director Derica W. Rice Acquires Deferred Share Units

Bristol-Myers Squibb Company Director Derica W. Rice has acquired 810.11 Deferred Share Units, increasing her beneficial ownership to 32,497.258 units.

Summary

• Derica W. Rice, a Director of Bristol-Myers Squibb Co (BMY), acquired 810.11 Deferred Share Units.
• The transaction date for the acquisition was June 30, 2025.
• Each Deferred Share Unit will convert into one share of common stock upon settlement.
• Settlement of the units occurs when the reporting person ceases to be a director or at a previously specified future date.
• Following this transaction, Derica W. Rice beneficially owns a total of 32,497.258 Deferred Share Units.
• The total beneficial ownership includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates director alignment with shareholder interests through equity compensation, which is a standard and expected practice.

Positives

• The acquisition of Deferred Share Units by a director aligns the director's interests with those of the shareholders, indicating confidence in the company's future performance.
• The units are part of a compensation plan, reflecting a structured approach to executive and director incentives.

Future Outlook

Deferred Share Units will convert into common stock upon the reporting person ceasing to be a director or at a future date previously specified by the reporting person.

Industry Context

This filing represents a routine insider transaction related to director compensation within the pharmaceutical industry, reflecting standard corporate governance practices for aligning director interests with company performance.

Related Party Transactions

• The acquisition of Deferred Share Units by Derica W. Rice, a director of Bristol-Myers Squibb, constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The transaction aligns the director's financial interests with the company's long-term performance, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• The Deferred Share Units will be converted into common stock upon Derica W. Rice ceasing to be a director or at a future date previously specified by her.

Key Dates

Keywords

Bristol-Myers Squibb, BMY, SEC Form 4, Insider Transaction, Deferred Share Units, Director Compensation, Equity Compensation, Beneficial Ownership